EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer

Esther Visser, Sylvia A A M Genet, Remco P P A de Kock, Ben E E M van den Borne, Maggy Youssef-El Soud, Huub N A Belderbos, Gerben Stege, Marleen E A de Saegher, Susan C van 't Westeinde, Luc Brunsveld, Maarten A C Broeren, Daan van de Kerkhof und 3 weitere

Lung Cancer · 2023

DOI: 10.1016/j.lungcan.2023.01.014 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Lung Cancer, 2023. Verfasst von Esther Visser und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands; Catharina Hospital Eindhoven, Eindhoven, the Ne…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Pathologic subtyping of tissue biopsies is the gold standard for the diagnosis of lung cancer (LC), which could be complicated in cases of e.g. inconclusive tissue biopsies or unreachable tumors. The diagnosis of LC could be supported in a minimally invasive manner using protein tumor markers (TMs) and circulating tumor DNA (ctDNA) measured in liquid biopsies (LBx). This study evaluates the performance of LBx-based decision-support algorithms for the diagnosis of LC and subtyping into small- and non-small-cell lung cancer (SCLC and NSCLC) aiming to directly impact clinical practice. MATERIALS AND METHODS: In this multicenter prospective study (NL9146), eight protein TMs (CA125, CA15.3, CEA, CYFRA 21-1, HE4, NSE, proGRP and SCCA) and ctDNA mutations in EGFR, KRAS and BRAF were analyzed in blood of 1096 patients suspected of LC. The performance of individual and combined TMs to identify LC, NSCLC or SCLC was established by evaluating logistic regression models at pre-specified positive predictive values (PPV) of ≥95% or ≥98%. The most informative protein TMs included in the multi-parametric models were selected by recursive feature elimination. RESULTS: Single TMs could identify LC, NSCLC and SCLC patients with 46%, 25% and 40% sensitivity, respectively, at pre-specified PPVs. Multi-parametric models combining TMs and ctDNA significantly improved sensitivities to 65%, 67% and 50%, respectively. CONCLUSION: In patients suspected of LC, the LBx-based decision-support algorithms allowed identification of about two-thirds of all LC and NSCLC patients and half of SCLC patients. These models therefore show clinical value and may support LC diagnostics, especially in patients for whom pathologic subtyping is impossible or incomplete.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansProspective StudiesBiomarkers, TumorPhosphopyruvate HydrataseLiquid BiopsyAntigens, NeoplasmKeratin-19

Stichwörter der Autor:innen

Decision–support algorithmLiquid biopsyLung cancerProtein tumor markerscirculating tumor DNA

Substanzen

Biomarkers, TumorPhosphopyruvate Hydrataseantigen CYFRA21.1Antigens, NeoplasmKeratin-19

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands; Catharina Hospital Eindhoven, Eindhoven, the Netherlands; Máxima Medical Center, Eindhoven/Veldhoven, the Netherlands…
  • Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands; Catharina Hospital Eindhoven, Eindhoven, the Netherlands; Expert Center Clinical Chemistry Eindhoven, Eindhoven, the…
  • Catharina Hospital Eindhoven, Eindhoven, the Netherlands.
  • Máxima Medical Center, Eindhoven/Veldhoven, the Netherlands.
  • Amphia Hospital, Breda, the Netherlands.
  • Anna Hospital, Geldrop, the Netherlands.

Förderung

  • AstraZeneca
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Visser, E., Genet, S. A. A. M., de Kock, R. P. P. A., van den Borne, B. E. E. M., Youssef-El Soud, M., Belderbos, H. N. A., Stege, G., de Saegher, M. E. A., van 't Westeinde, S. C., Brunsveld, L., Broeren, M. A. C., van de Kerkhof, D., Deiman, B. A. L. M., Eduati, F., & Scharnhorst, V. (2023). Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer. Lung Cancer. https://doi.org/10.1016/j.lungcan.2023.01.014

Vancouver

Visser E, Genet SAAM, de Kock RPPA, van den Borne BEEM, Youssef-El Soud M, Belderbos HNA, et al. Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer. Lung Cancer. 2023. doi:10.1016/j.lungcan.2023.01.014

BibTeX
@article{Visser2023,
  author = {Visser, Esther and Genet, Sylvia A A M and de Kock, Remco P P A and van den Borne, Ben E E M and Youssef-El Soud, Maggy and Belderbos, Huub N A and Stege, Gerben and de Saegher, Marleen E A and van 't Westeinde, Susan C and Brunsveld, Luc and Broeren, Maarten A C and van de Kerkhof, Daan and Deiman, Birgit A L M and Eduati, Federica and Scharnhorst, Volkher},
  title = {Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer},
  journal = {Lung Cancer},
  year = {2023},
  doi = {10.1016/j.lungcan.2023.01.014}
}
Kostenlos starten →